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Vitamin D (VD) is a known differentiating agent, but
the role of VD receptor (VDR) is still incompletely
described in acute myeloid leukemia (AML), whose
treatment is based mostly on antimitotic chemo-
therapy. Here, we present an unexpected role of
VDR in normal hematopoiesis and in leukemogen-
esis. Limited VDR expression is associated with
impaired myeloid progenitor differentiation and is a
new prognostic factor in AML. In mice, the lack of
Vdr results in increased numbers of hematopoietic
and leukemia stem cells and quiescent hematopoiet-
ic stem cells. In addition, malignant transformation of
Vdr/ cells results in myeloid differentiation block
and increases self-renewal. Vdr promoter is methyl-
ated in AML as in CD34+ cells, and demethylating
agents induce VDR expression. Association of VDR
agonists with hypomethylating agents promotes leu-This is an open access article under the CC BY-Nkemia stem cell exhaustion and decreases tumor
burden in AML mouse models. Thus, Vdr functions
as a regulator of stem cell homeostasis and leukemic
propagation.
INTRODUCTION
Acute myeloid leukemia (AML) is a heterogeneous disorder with
a poor prognosis and is themost frequent form of acute leukemia
in adults. Recently, it has been shown that disease heterogeneity
is derived from differences in somatic mutations among individ-
ual patients (Patel et al., 2012). Recurrent mutations in normal
karyotype AML (which constitutes nearly 50% of cases) target
a set of approximately 30 genes, most frequently FLT3, NPM1,
KIT, CEBPA, andMLL (Ley et al., 2013; Patel et al., 2012; Welch
et al., 2012). These mutations affect self-renewal, cell survival
and proliferation, and myeloid differentiation, impairing hemato-
poiesis and promoting accumulation of undifferentiated blasts
(Ferrara and Schiffer, 2013; Lo¨wenberg et al., 1999; Mardis
et al., 2009).Cell Reports 30, 739–754, January 21, 2020 ª 2019 739
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Vitamin D (VD), whose availability modulates hematopoietic
stem and progenitor cell (HSPC) production (Cortes et al.,
2016), has potential antineoplastic properties (Campbell and
Trump, 2017; Giovannucci et al., 2006). VD promotes cell differ-
entiation in numerous tissues, such as prostate, breast, and the
hematopoietic system (Jacobs et al., 2016; Samuel and Sitrin,
2008), through genomic activity that relies mostly on its associa-
tion with VD receptor (VDR). In addition, VDR targets genes that
are essential to cell cycle progression, another cancer feature
(Campbell and Trump, 2017; Samuel and Sitrin, 2008). There-
fore, VDR is a promising target in cancer therapy. VDR belongs
to the nuclear receptor family, such as the retinoic acid receptor
(RAR), which is implicated in leukemogenesis in acute promyelo-
cytic leukemia (APL), an AML subtype related to the t(15;17)
translocation (Arber et al., 2016). The use of suprapharmacologic
dose of RAR agonist (RARa) in APL has permitted a major
advance in AML therapy through the targeting of leukemia
stem cells (LSCs) (Ablain et al., 2013, 2014). However, clinical tri-
als with VD analogs in AML have been disappointing, mostly
because of adverse effects such as life-threatening hypercalce-
mia (Cao et al., 2017; Kim et al., 2012).
Despite chemotherapy and allogeneic stem cell transplanta-
tion regimens, AML management remains a challenge. Although
many leukemic cells are typically sensitive to chemotherapy, re-
lapses occur frequently and most of the time lead to death. Re-
lapses result from the failure of available therapies to eradicate
LSCs, which are able to self-renew, expand, and reestablish
the disease (Bonnet and Dick, 1997; Passegue´ and Weisman,
2005; Terpstra et al., 1996). Therefore, therapies aiming to target
LSCs (while preserving hematopoietic stem cells [HSC]) should
help improve therapeutic efficacy and patient survival.
DNAmethylation plays a critical role in AML pathogenesis, and
different AML subtypes are characterized by distinct epigenetic
signatures (Akalin et al., 2012; Figueroa et al., 2010), thus
providing insight into the potential for treatment options
(Abdel-Wahab and Levine, 2013). Moreover, in myelodysplastic
syndromes (MDS), DNAmethylation predicts response to deme-
thylating agents (Shen et al., 2010), and the use of DNA methyl-
transferase inhibitors (e.g., 5-azacytidine [5-aza], decitabine
[DAC]) decreases rates of AML transformation (Fenaux et al.,
2010). However, response rates are short lived, and the
molecular mechanisms underlying the efficacy of DNA methyl-
transferase inhibitors are not well understood (Garcia-Manero
and Fenaux, 2011).
We have previously shown that iron deprivation therapy pro-
motes monocytic differentiation of AML cells (Callens et al.,
2010a). Analysis of gene expression patterns revealed that
30% of the most significant genes induced by therapy targeting
iron homeostasis presented a VDR signaling signature. Iron
chelating agents acted synergistically with 1,25-dihydroxyvita-
min D3 through the induction of VDR signaling and activation
of the downstream mitogen-activated protein kinase (MAPK)
pathway. Moreover, we showed that combined therapy with
iron chelators and VD was associated with increased overall sur-
vival (OS) in a retrospective cohort of elderly patients and that
circulating VD levels predicted OS in AML (Paubelle et al.,
2013), an observation that was confirmed by others (Lee et al.,
2014; Paubelle et al., 2013). Therefore, induction of VDR expres-740 Cell Reports 30, 739–754, January 21, 2020sion and activity represents a potential therapeutic target in
AML, particularly in elderly patients non-eligible for intensive
chemotherapy or allogeneic bone marrow transplantation
(BMT) (Ferrara, 2014; Russell, 2012).
Here, we investigated the correlation between VDR expres-
sion and activity and the molecular mechanisms involved in
AML pathogenesis. We show that Vdr expression is downregu-
lated by DNA methylation and that low expression of Vdr is
involved in HSC and LSC homeostasis with important implica-
tions for AML prognosis and therapy.
RESULTS
Vdr Expression Is Associated with Monocyte
Differentiation and Patient Survival in AML
VD is a compound well known to induce AML differentiation, but
the role of VDR has never been investigated in leukemogenesis.
To evaluate VDR expression and activity in AML, we analyzed a
previously published gene expression dataset (GEO: GSE12417)
(Metzeler et al., 2008) that includes normal karyotype AML pa-
tients (n = 163) classified according to the French-American-
British (FAB) system (Bennett et al., 1976). In this patient cohort,
we found that Vdr expression was higher in AML subtypes with
features of monocytic differentiation (AML4 and AML5)
compared with immature or undifferentiated AML subtypes
(AML0, AML1, and AML2). Not surprisingly, AML6 subtype ex-
hibited a low level of Vdr expression (Figure 1A). Expression of
monocyte differentiation markers such as CD14 and CSF1R
(Friedman, 2002) did not differ between AML0–2 and AML4–5
subtypes (Figures S1A and S1B), suggesting that these markers
do not correlate with morphological monocyte differentiation in
AML subtypes. In contrast, there was an increased CAMP,
CYP27B1, andCYP24A1 expression in AML4 and AML5 patients
(Figures S1C–S1E), suggesting that, given that those genes are
downstream positive targets of VDR signaling (Ma et al., 2012),
increased Vdr expression was associated with induction of
VDR signaling. Therefore, undifferentiated and immature AML
subtypes showed decreased Vdr expression compared with
AML subtypes displaying monocytic differentiation.
VD is well known for its ability to inducemyeloid progenitor dif-
ferentiation into monocytes (Munker et al., 1986; Nagler et al.,
1986), and its activity relies on the expression of its receptor.
To quantify Vdr expression in samples from healthy individuals
and AML patients, we conducted an additional retrospective
analysis (GEO: GSE9476) (Stirewalt et al., 2008), confirming
higher Vdr expression in AML4–5 subtypes compared with
AML0–2 subtypes (Figure 1B). This analysis also revealed that
Vdr expression in AML0–2 patients did not differ from that
observed in CD34+ cells purified from bone marrow of healthy
subjects or from peripheral blood in granulocyte colony-stimu-
lating factor (G-CSF)-mobilized healthy donors (Figure 1B).
Moreover, Vdr expression was similar between AML4–5 sub-
types and bone marrow mononuclear cells (BMMCs) from
healthy subjects (Figure 1B), but Vdr expression in AML4–5 sub-
types was decreased in comparison with peripheral blood
mononuclear cells (PBMCs) from healthy subjects (Figure 1B).
Further investigation of Vdr expression during human normal he-
matopoiesis (http://servers.binf.ku.dk/hemaexplorer) confirmed
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that Vdr expression was low in hematopoietic progenitors and
myeloid precursors and was increased in fully differentiated
monocytes (Figure S2A). Therefore, Vdr expression in normal he-
matopoietic cells tracks with terminal monocyte differentiation.
To gain insight into the consequences of decreased Vdr
expression in AML cells, we used hematopoietic precursors
from Vdr-knockout mice (Vdr/) (Van Cromphaut et al., 2001)
transformed by retrovirus transduction of AML or myeloprolifer-
ative neoplasm (MPN)-associated oncogenes such as MLL-ENL
or MLL-AF9 fusion genes or mutant FLT3 (internal tandem dupli-
cation [Flt3-ITD]). Monocyte differentiation was evaluated using
flow cytometry with anti-CD11b and F4/80 (a widely usedmarker
of murine macrophage population) antibodies and by cell
morphology (May-Gr€unwald Giemsa staining). In the absence
of transduction, there was no difference between Vdr+/+ and
Vdr/ blood cell differentiation (data not shown). Transduction
of Vdr/ hematopoietic precursors resulted in a dramatic in-
crease in undifferentiated CD11b F4/80 double-negative
cells (Figure 1C; Figure S2B) and relatively less mature
morphology (Figure 1D) compared with transduced wild-type
(WT) cells, suggesting that Vdr inactivation is sufficient to limit
myeloid differentiation in AML/MPN models.
To investigate the clinical relevance of Vdr expression in the
pathogenesis of AML, we examined its relationshipwith patients’
prognosis. Because Vdr expression was low in AML0–2 patients,
we analyzed the outcome of variations in baseline Vdr expres-
sion only in AML4–5 patients from the GEO: GSE12417 series
(n = 62 patients). OS was evaluated in patients with high (third
tertile, n = 21 patients), intermediate (second tertile, n = 20 pa-
tients), and low (first tertile, n = 21 patients) Vdr expression.
Log rank analysis of plotted curves showed that patients with
higher Vdr expression had increased OS compared with those
with lower Vdr expression (Figure 1E). Thus, Vdr expression
could be used to refine patients’ prognosis in AML4–5.
We also evaluated the impact of VDR signaling on AML relapse
by analyzing the expression of VDR-target genes. For these
experiments, we analyzed the expression level of cathelicidin anti-
microbial peptide gene (CAMP) in a third cohort of well-defined
patients treated with conventional chemotherapy regimens (all
AML subtypes included except AML3; n = 90) (Castaigne et al.,
2012). Our results demonstrate that patients with elevatedFigure 1. Vdr Expression Is Associated with Differentiation and Surviv
(A and B) Vdr expression tracks with myeloid differentiation in AML and healthy s
(A) Retrospective analysis of a GenBank dataset study (GEO: GSE12417; n = 1
karyotype AML patients.
(B) Retrospective analysis of a GenBank dataset study (GEO: GSE9476 series) sh
cells, n = 8; peripheral blood CD34+ cells purified from G-CSF-mobilized donors,
mononuclear cells [PBMCs], n = 10) and leukemic blasts from AML patients clas
(C and D) Limited myeloid differentiation in Vdr/ transformed cells.
(C) Bone marrow hematopoietic precursors from Vdr/ and WT mice (BALB/c ba
Flt3-ITD. Cell differentiation was evaluated using flow cytometry with CD11b pan-m
R 3 mice per group).
(D) Cell morphology (May-Gr€unwald Giemsa [MGG] staining) from cells generate
(E–G) Vdr and VDR-targeted gene expression correlates with AML prognosis. Ov
subtypes; n = 62) according to Vdr expression. Log rank analysis comparing dif
expression (low Vdr expression [n = 21, black line], medium Vdr expression [n = 2
(EFS; F) and relapse-free survival (G) log rank analysis according to CAMP express
line]; n = 30 for each).
Data obtained from Castaigne et al. (2012). All results are presented as mean ± S
742 Cell Reports 30, 739–754, January 21, 2020CAMP expression (a VDR-targeted gene) (n = 30,third tertile) ex-
hibited an increased event-free survival (EFS) and relapse-free
survival (RFS) compared with those with lower CAMP expression
(n = 30, first tertile) (Figures 1F and 1G). Analysis of these AML pa-
tients also revealed increased Vdr expression in AML4–5 relative
to AML0–2 subtypes (Figure S3A), further confirming observations
from gene set databases GEO: GSE12417 and GEO: GSE9476.
Moreover, in the GEO: GSE12417 cohort also, expression of
CAMP and CYP27B1 correlated with survival (Figures S3B and
S3C). We also performed analysis on The Cancer Genome Atlas
(TCGA) cohort (Ley et al., 2013). Vdr expression was higher in
AML4–5 subtypes (Figure S3D), and survival analysis performed
on low and intermediate cytogenetics AML4–5 revealed an
increased OS with high VDR (Figure S3E) or high CAMP (Fig-
ure S3F) expression. Taken together, these data correlate Vdr/
VDR-target gene expression with improved prognosis in AML pa-
tients and with features of monocyte differentiation.
Vdr Inactivation Decreased Myeloid Precursor Numbers
Undergoing Monocyte Differentiation and Increased
HSC Engraftment
To gain further insight into the role of VDR in AML cells, we
analyzed VDR involvement in hematopoiesis. Previous studies
showed that Vdr/ mice have normal numbers of circulating
monocytes, suggesting that in steady state, VDR is not essential
for myeloid differentiation (O’Kelly et al., 2002). Complete blood
cell counts from Vdr/ andWTmice (both fed a standard diet) in
steady-state conditions confirmed and extended these results,
as no differences were observed in platelet, erythrocyte, granu-
locyte, andmonocyte numbers between the two genotypes (Fig-
ure 2A and data not shown). In addition, there was no difference
in cell numbers between Vdr/ and WT animals in both bone
marrow and spleen (Figure 2B). However, analysis of progenitor
cells revealed that common myeloid progenitors (CMPs) and
granulocyte-monocyte progenitors (GMPs) decreased in Vdr/
mice comparedwithWTmice (Figures 2C and 2D). In agreement,
colony-forming cell (CFC) assays revealed that the ratio of
macrophage (M) to granulocyte (G) colonies is decreased in
Vdr/ bone marrow (Figure 2E). Thus, the decreased number
of monocyte progenitors in Vdr/ mice suggests that VDR
expression drives monocyte differentiation.al in AML
amples.
63) showing Vdr expression according to FAB subtype in a cohort of normal
owing Vdr expression in healthy samples (including bone marrow [BM] CD34+
n = 10; bone marrow mononuclear cells [BMMCs], n = 10; and peripheral blood
sified according to their FAB subtype (AML0–2, n = 8; AML4–5, n = 9).
ckground) were transduced with retrovirus coding for MLL-ENL, MLL-AF9, or
yeloid and F4/80monocytemarkers. Results are presented asmean ±SEM (n
d in (C).
erall survival of patients from GEO: GSE12417 series (a pool of AML4 or AML5
ferent groups of patients (separated into tertiles) according to the relative Vdr
0, red line], and high Vdr expression [n = 21, green line]) (E). Event-free survival
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We then evaluated whether and how Vdr inactivation affects
HSCs and hematopoietic progenitor cells (HPCs). Flow cytome-
try analyses of Vdr/ mouse bone marrow cells revealed an in-
crease in long-term HSCs (LT-HSCs) but not short-term HSCs
(ST-HSC) in Vdr/ mice (Figure 2F; Table S1). To investigate
the role of VDR in HSC self-renewal potential, Vdr WT and
Vdr/ bone marrow cells were plated in methylcellulose and
colonies were counted between days 7 and 10 of culture.
Following serial replating, Vdr/ cellsmaintained significant clo-
nogenic potential in contrast to WT cells (Figure 2G). We then
exposed Vdr WT and Vdr/ mice to sublethal total body irradi-
ation and monitored hematopoietic recovery. Vdr/ mice
showed a milder decrease of circulating mononuclear cells
(MNC) and faster recovery (Figure 2H). To confirm these data,
we performed competitive transplants. CD45.2 bone marrow
cells from VdrWT or Vdr/mice were infused to sublethally irra-
diated mice together with Vdr WT CD45.1 competitive bone
marrow cells. Recipient mice showed an increased level of blood
and bone marrow donor chimerism with Vdr/ cells (Figure 2I).
Subpopulation analysis showed decreased donor chimerism in
CMP and GMP with Vdr/ cells (Figure 2J). However, donor
chimerismwas increased in LT-HSC and ST-HSCwhen recipient
mice were transplanted with Vdr/ cells (Figure 2K). These data
further support the role of Vdr in hematopoietic differentiation
and in the homeostasis of HSC pool.
Prior literature suggests that low reactive oxygen species
(ROS) levels increase HSC longevity, and high ROS levels pro-
mote myeloid differentiation (Callens et al., 2010a, 2010b; Jung
et al., 2013; Tothova et al., 2007). Because ROS control HSC ho-
meostasis, we evaluated ROS levels in LinSca-1+c-Kit+ (LSK)
cells by using the ROS indicator CM-H2DCFDA. Vdr
/mice ex-
hibited decreased numbers of LSK cells expressing high ROS
levels compared with WT controls (Figure S4). As steady-state
HSC maintenance depends on their quiescent state (Passegue´Figure 2. Vdr Inactivation Decreases Myeloid Precursors Engaged in M
(A) In steady-state conditions, Vdr/ mice present normal numbers of white
monocyte numbers in 8- to 16-week-old WT (n = 7) and Vdr/ (n = 7) mice.
(B) In steady-state conditions, Vdr-deficient mice present normal cellularity in bon
cellularity of 24-week-old WT (n = 3) and Vdr/ (n = 3) mice.
(C) Representative fluorescence-activated cell sorting (FACS) staining profiles of t
myeloid progenitor; GMP, granulocyte/macrophage progenitor; LK, LinKit+; L
hematopoietic stem cell; MEP, megakaryocyte/erythroid progenitor; ST-HSC, sh
(D) Decreased numbers of hematopoietic progenitors in Vdr/mice. Multiparame
in the bone marrow of WT and Vdr/ 12-week-old mice (n = 6–8 mice per group
(E) Reduced numbers of monocyte progenitors in Vdr/ mice. CFC assays of b
(F) Increased numbers of LT-HSCs in Vdr/mice.Multiparametric flow cytometry
12-week-old WT and Vdr/ mice (n = 6–8 mice per group). The proportion of a
(G) Increased clonogenic potential of Vdr/ cells. WT and Vdr/ primary hema
ylcellulose media containing cytokines (M-3434) and scored following 7–10 days
Histograms represent numbers of colonies (n = 3; nR 6 mice per group).
(H) Increased hematopoietic recovery in Vdr/ mice. WT and Vdr/ mice (n =
(MNCs) were monitored for 46 days.
(I) Increased engraftment of Vdr/ BM cells. Competitive transplantation assays
CD45.1 BM WT competitor cells (n = 3 mice per group).
(J) Reduced numbers of monocyte progenitors with Vdr/ BM cells in competit
(K) Increased number of HSC with Vdr/ BM cells in competitive transplantation
(L) Hematopoietic precursors from Vdr-deficient mice presented an increased qu
marrow LSK cells from WT and Vdr/ mice (n = 6 mice per group); left: represe
(M) Quantification of quiescent status.
Results are presented as mean ± SEM; nR 3. ns, not significant; *p < 0.05, **p
744 Cell Reports 30, 739–754, January 21, 2020et al., 2005), we searched for differences in cell cycle between
WT and Vdr/ progenitors. LSK cells from Vdr/ mice had an
increased percentage of quiescent G0 cells and a decreased
percentage of cycling G1 and S-G2/M cells (Figures 2L and
2M) relative to WT controls. Altogether these results show that
VDR increases ROS level and quiescence-to-cell-cycling transi-
tion in HSCs.
Vdr Invalidation inOncogene-TransformedCells Results
in AMLwith Increased Leukemic Colony-Forming Ability
To further investigate the impact of Vdr expression in hematopoi-
etic progenitors in a leukemic context, we first studied the
expression of phenotypic markers in hematopoietic progenitors
from WT and Vdr/ mice transformed with Flt3-ITD, MLL-ENL,
andMLL-AF9 fusion proteins. Usingmultiparametric flow cytom-
etry analysis, an increased proportion of LSK cells was observed
in Vdr/ relative to WT transformed cells (Figure 3A).
Then, in order to examine the role of Vdr in LSC self-renewal
potential, oncogene-transformed cells were plated in methylcel-
lulose, and colonies were counted between days 7 and 10 of cul-
ture. The first round of plating revealed similar CFC numbers
from WT and Vdr/ transformed cells (Figure 3B). However,
following serial replating (and as observed with non-transformed
cells; see Figure 2G), Vdr/ transformed cells maintained signif-
icant clonogenic potential in contrast to WT cells (Figure 3C).
Thus, Vdr/ hematopoietic progenitors showed an enhanced
clonogenic potential whether or not after oncogenic transforma-
tion. Furthermore, expression of LSK-related genes (EVI-1,
HOXA-9, and MEIS-1), typically downregulated in committed
myeloid progenitors (Chen et al., 2008), was increased in Vdr/
relative toWT transformed cells (Figure 3D) suggesting that inac-
tivation of Vdr in oncogene-transformed cells results in a more
immature phenotype, in line with our previous observations in
healthy progenitor cells.onocyte Differentiation and Increases Number of HSC
blood cells (WBCs), monocytes, and granulocytes. WBC, granulocyte, and
e marrow and spleen. Cellularity of the bone marrow of one femur and spleen
he progenitor populations. CLP, common lymphoid progenitor; CMP, common
SK, LinKit+Sca-1+; LRP, lineage-restricted progenitor; LT-HSC, long-term
ort-term hematopoietic stem cell.
tric flow cytometry quantification of hematopoietic progenitor cell populations
).
one marrow cells from WT and Vdr/ mice (nR 4 mice per group).
quantification of hematopoietic precursors cells populations in bonemarrow of
given population among total viable bone marrow cells is indicated.
topoietic progenitors were plated (30,000 cells/condition) in semisolid meth-
of culture. For replating assays, 30,000 cells were plated for each condition.
6 mice per group) were exposed to 4.5 Gy, and circulating mononuclear cells
were performed with 500,000 Vdr WT or Vdr/ CD45.2 BM cells and 500,000
ive transplantation assays.
assays.
iescent status. Cell cycle analyses performed by Ki67 and PI labeling of bone
ntative histogram; right: mean ± SEM percentages of G0 cells are plotted.
< 0.01, and ***p < 0.001.
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Finally, evaluation of the consequences of Vdr deletion in tumor
initiation and progression was performed by crossing Vdr/mice
with mice transformed with Flt3-ITD that develop myeloprolifera-
tive disease resembling chronic myelomonocytic leukemia
(CMML). Competitive grafts were performed, and chimerism
was analyzed according to the expression of Ly5.1 (Figure 3E).
These cells present a higher capacity of engraftment during the
first grafts, especially a better graft of pathological cells character-
ized by the expression ofMac1 andGr1 (Figure 3F). Nevertheless,
secondary grafts suggest that in this transformationmodel, lack of
Vdr is not an initiating event of leukemogenesis, and these cells
have a slightly increased capacity for grafting without over-repre-
sentation of leukemic cells (Figure 3G).
Taken together, we demonstrate, using three different models
of leukemic transformation, that Vdr/ cells have an immature
phenotype relative to WT cells associated with increased clono-
genicity, suggesting that impaired Vdr expression favors an
immature state of AML cells.
PromoterMethylation Decreases Vdr Expression in AML
Cells, and Sensitivity to DNA Methyltransferase
Inhibitors Is Dependent on Vdr Expression
To evaluate the molecular mechanisms of decreased Vdr
expression in AML cells, we focused on the methylation profile
of CpG islands (Akalin et al., 2012) in methylation-susceptible
Vdr promoter region (Marik et al., 2010). Analysis of the Vdr pro-
moter from a previously published gene expression dataset
(GEO: GSE18700) of 344 AML patients and 8 normal CD34+
cell samples revealed an important methylation of three clusters
out of four that did not differ between AML and CD34 samples
(Figure 4A). In vitro treatment with the DNAmethyltransferase in-
hibitor 5-aza promoted a 2-fold increase in Vdr expression rela-
tive to vehicle in HL60 cells (Figure 4B). In addition, 5-aza, like the
VDR agonists VD and inecalcitol (INEC), induced the expression
of VDR-target genes CAMP and CYP24A1 in HL60 (Figure 4C)
and primary AML cells (Figure 4D), suggesting that demethylat-
ing agents induce Vdr expression.
We then examined whether the anti-leukemic action of 5-aza
on AML cells depends, at least in part, on its ability to induce
Vdr expression and VDR-target genes. To explore this hypothe-
sis, we studied the consequences of Vdr invalidation on AML cell
sensitivity to 5-aza under pharmacological conditions (Fenaux
et al., 2010). MLL-ENL-, Flt3-ITD-, and MLL-AF9-transformed
WT cells were sensitive to 5-aza in a dose-dependent manner,Figure 3. Oncogene Transformation of Vdr/ Is Associated with Increa
Forming Ability
(A) Increased frequency of LSK cells in Vdr/ transformed cells. Left: representa
cells following leukemic transformation with MLL-AF9 oncogene. Right: quantifica
MLL-ENL, MLL-AF9, or Flt3-ITD (nR 3 mice per group).
(B and C) Increased clonogenic potential of Vdr/ transformed cells. Oncogene
(30,000 cells/condition) in semisolid methylcellulose media containing cytokines
cells were plated for each condition. Histograms represent numbers of colonies
(D) Increased expression of stemness-related genes in Vdr/ transformed cells. W
1, HOXA-5, HOXA-9, and MEIS-1 using qPCR analysis (nR 3 mice).
(E) Experimental protocol used to investigate the competitive repopulating ability
(F) Increased peripheral blood engraftment in first transplantation assays with Vd
(G) Increased bone marrow engraftment in second transplantation assays with V
All results are presented as mean ± SEM; nR 3. ns, not significant; *p < 0.05, **
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Vdr/ cell survival was not altered by 5-aza treatment (Figures
4E and 4F). Taken together, these data indicate that in AML
and normal cells, methylation of Vdr promoter controls Vdr
expression, which in turn controls cell sensitivity to 5-aza.
Combined Demethylating Agents and VDR Agonists
Synergistically Induced Cell Differentiation, Cell-Cycle
Arrest, and Apoptosis in AML Cells, Resulting in
Decreased Tumor Progression in Mice
VDR agonists promote monocyte differentiation in AML cells
(Amento et al., 1984; Nagler et al., 1986). However, life-threat-
ening hypercalcemia prevented the observation of clinical re-
sponses in clinical trials using VD (Kim et al., 2012). INEC is a
highly potent VDR agonist able to induce cell-cycle arrest in he-
matopoietic cells (Kim et al., 2012; Petrini et al., 1991) that has
been developed to avoid hypercalcemia in patients with hemato-
logical malignancies, while maintaining proliferation inhibition of
tumor cells (Kim et al., 2012; Petrini et al., 1991; Figure 5A). Dose-
response curves demonstrated that INEC was approximately
500 times more effective than VD in promoting AML cell differen-
tiation (Figure 5B; Figure S5A). Because Vdr expression was
reduced in AML cells, we postulated that combination of 5-aza
and INEC would increase Vdr expression by decreasing pro-
moter methylation and activate VDR, respectively. Whereas
5-aza, VD, or INEC alone promoted amodest increase inmyeloid
differentiation, their combined use led to a significant increase in
differentiation as determined by CD14 and CD11b expression in
normal CD34+ cells, primary AML cells and AML cell lines, and
HL60 cells (Figure 5C; Figures S5B, S5C, and S7A). Further
morphological analysis confirmed these observations in HL60
cells (Figure S5D). This synergistic effect on differentiation was
also observed in the mRNA expression of monocyte differentia-
tion markers (TREML2, SERPINB8), which were upregulated in
cells treated with VD agonists and demethylating agent (Fig-
ure 5D; Figure S5F). Moreover, in HL60 cells, granulocyte marker
expression (NE, PRTN3) was downregulated in comparison with
controls, suggesting that this drug association favors monocyte
differentiation over granulocyte differentiation (Figure 5D), as
previously shown for VD (Callens et al., 2010a). As expected,
the synergistic effect between VDR agonists and DNA methyl-
transferase inhibitors was not restricted to 5-aza, as DAC
showed a similar ability in promoting AML cell differentiation
(Figure S6).sed Frequency of Hematopoietic Progenitors and Increased Colony-
tive dot plots of LinSca-1+KIT+ (LSK) cells from WT and Vdr/ bone marrow
tion of LSK+ cells in WT and Vdr/ cells transduced with retrovirus coding for
-transformed WT and Vdr/ primary hematopoietic progenitors were plated
and scored following 7–10 days of culture (B). For replating assays (C), 30,000
(n = 3; six mice per group).
T and Vdr/ Flt3-ITD-transformed cells were analyzed for expression of EVI-
of Vdr+/+ or Vdr/ 3 Flt3-ITD cells.
r/ 3 Flt3-ITD cells.
dr/ 3 Flt3-ITD cells.
p < 0.01, and ***p < 0.001.
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Figure 4. Promoter Methylation Limits Vdr Expression in Normal CD34+ and AML Cells, and Vdr/ Cells Are Resistant to Hypomethylating
Agents
(A) Vdr promoter is methylated in normal CD34+ and in AML cells. Retrospective analysis of a GenBank dataset study (GEO: GSE18700; n = 344 AML samples
and n = 8 CD34+ cell samples) showing four clusters of methylation on Vdr promoter.
(B and C) 5-aza treatment induces Vdr and VDR-target gene expression in HL60 and primary AML cells. HL60 cells were cultured with and without 5-aza (5 mM) or
VD (1 mM; as positive control) for 6 h to analyze Vdr expression (B) and that of VDR-target genes (C) using qPCR.
(D) Primary AML cells (n = 3 patients) were cultured with and without 5-aza (5 mM), the VDR agonist inecalcitol (INEC; 10 nM), or both for 6 h. Vdr expression or that
of VDR-target genes (CAMP and CYP24A1) was evaluated using qPCR.
(E and F) Vdr/ transformed cells are resistant to 5-aza treatment. MLL-ENL (E), Flt3-ITD, and MLL-AF9 (F) transformed WT and Vdr/ cells were cultured with
and without increasing concentrations of 5-aza for 72 h. Cell viability was evaluated using ATP assay.
Results are presented as mean ± SEM. ns, not significant; *p < 0.05, **p < 0.01, and ***p < 0.001.
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Combined 5-aza/INEC association was also effective in
inducing cell-cycle arrest (Figure 5E) and upregulation of cy-
clin-dependent kinase (cdk) inhibitors including p15, p21, and
p27 (Figure 5F; Figures S7A and S7B). But there was no additive
or synergistic effect in inducing apoptosis (Figure S7C) of
leukemic cell lines as evidenced by annexin V-positive and TO-
PRO-3 negative staining, further suggesting that the association
provides significant anti-leukemic effects. Mice passively trans-
ferred with Flt3-ITD/Npm1c AML blasts (Mupo et al., 2013) and
treated in vivo with INEC and DAC presented increased survival
compared with vehicle-treated or DAC-treated animals (Fig-
ure S7D). In another in vivo tumor xenograft model with U937
cell line, 5-aza/INEC therapy resulted in an increased survival
compared with control.
In this in vivo model (Figure 5G), we did not observe a signifi-
cant effect on survival or tumor growth of single treatments
with 5-aza or INEC (Figure 5H), indicating a combined effect of
this regimen. Altogether, these results indicate that when used
in combination, VDR agonists and demethylating agents act to
activate VDR signaling resulting in impaired growth, increased
differentiation, and apoptosis of AML cells in vitro and in vivo.
Targeting VDR Signaling Impairs Colony-Forming Ability
and LSC Pool in AML Models
LSCs are a relatively more quiescent subset of leukemic cells.
However, they can be followed functionally by their ability tomain-
tain clonogenicity in serial replating assays and to sustain leuke-
mia initiation and resistance to chemotherapy, and therefore
they are believed to be responsible for relapses. Because of the
hematological characteristics observed in Vdr/ mice, we hy-
pothesized that VDR agonists could efficiently target LSCs. First,
to test this hypothesis in vitro, weperformed serial replating exper-
iments with bone marrow precursors from WT mice transduced
with the Flt3-ITD construct in semisolid media containing INEC
or vehicle (Figure 6A). Flt3-ITD-transformed cells in INEC contain-
ing cultures exhibited a 2-fold decrease in clonogenic potential
compared with vehicle-treated cells upon first replating (Fig-
ure 6A). Subsequent replating revealed that INEC treatment
induced a progressive loss of LSCswith virtually no colony growth
at the fourth round of plating relative to vehicle-treated cells (Fig-
ure 6A). To examine if the INEC effect was reversible, INEC-Figure 5. 5-aza and VDR Analogs Synergize to Promote AML Cell Diffe
(A) Structural formulas of 1,25-dihydroxyvitamin D3 (VD) and VDR agonist inecal
(B) U937 cells were treated with increasing doses of VD or INEC, and cell differe
(C and D) Hypomethylating agents synergize with VDR agonists to promote mye
(C) CD34+ cells (n = 4 independent samples) and AML primary cells (AML0–1, n =
both. CD14 expression was evaluated using flow cytometry. Results are shown
(D) HL60 cells were cultured with and without 5-aza (5 mM), VD (300 nM), or INEC (1
and monocyte differentiation genes (TREML2 and SERPINB8) was assessed usi
(E and F) Combined hypomethylating agents and VDR agonists induce cell-cycle
(E) HL60 cells were cultured with and without 5-aza (5 mM), INEC (10 nM), or bot
(F) Expression of cell cycle regulator genes p15, p21, and p27 was evaluated us
(G and H) Survival of mice treated with hypomethylating agents and VDR agonis
(G) Combined hypomethylating agents and VDR agonists induce cell-cycle arres
vehicle (PBS), 5-azacytidine (5 mg/kg via intraperitoneal injection three times wee
each group).
(H) Kaplan-Meier plot of survival of mice treated with vehicle (PBS), DAC (0.5 mg/k
intraperitoneal injection five days weekly) after transfer of 1 million Flt3-ITD/Npm
Results are presented as mean ± SEM; nR 3. ns, not significant; *p < 0.05, **ptreated cultures were divided at the second plating stage into
two groups treated either with INEC or vehicle for the subsequent
rounds of replating (Figure 6A). INECwash-out reestablished CFC
numbers to levels observed in cells originally treated with vehicle
or induced a rebound to higher levels, suggesting that continuous
treatment with VDR agonists was required to maintain the selec-
tive pressure on colony forming cells (Figure 6A). Of note, when
the same experiments were performed with Flt3-ITD-transformed
Vdr/ cells, no effect of INEC was observed, demonstrating that
its effect relied on VDR (data not shown). Taken together, in vitro
colony replating assays suggest that (1) Vdr is implicated in the
control of LSC homeostasis and (2) VDR agonists have the poten-
tial to decrease their colony forming capacity.
We then tested the ability of VDR agonists to target LSC in vivo.
Flt3-ITD/Npm1c AML bone marrow cells (Mupo et al., 2013)
treated in vitrowith or without INEC for 6 days increased expres-
sion of myeloid differentiation markers compared with vehicle-
treated cells (Figure 6B). Mice adoptively transferred with these
INEC-treated cells did not develop aggressive leukemia
(Figure 6C). Immunophenotypic analysis of their blood cells did
not reveal the presence of leukemic cells, and their hemoglobin
levels and platelet numbers remained normal (Figure 6D). This
dramatically contrasted with mice transplanted with vehicle-
treated cells, which developed aggressive leukemia burden, as
evidenced by increased leukocyte numbers, anemia, and throm-
bocytopenia (Mupo et al., 2013; Figure 6D). Mice that underwent
adoptive transfer of vehicle-treated cells also demonstrated
decreased numbers of CD11b+Ly6G+ myeloid cells in both
bone marrow and spleen (Figure 6D) and splenomegaly (Fig-
ure 6E), features that were absent in mice that underwent adop-
tive transfer using INEC-treated cells. Finally, mice transplanted
with INEC-treated cells demonstrated a dramatic reduction in
mortality (Figure 6F). To further provide evidence that VDR tar-
geting decreases LSCs, we performed secondary transplanta-
tion using leukemic mice treated with the drugs in vivo (vehicle,
INEC, DAC, and DAC-INEC) and monitored disease progression
in the secondary recipient mice. In this setting, only DAC-INEC
and INEC-treated mice had significantly increased survival
(Figure 6G), without a difference between both treatments.
Therefore, in a Flt3-ITD/Npm1c model, VDR agonists control
LSC homeostasis in vitro and in vivo. They promoted growthrentiation and Reduce Tumor Growth
citol (INEC) (https://www.chemblink.com/products/163217-09-2.htm).
ntiation was evaluated by CD11b expression.
loid differentiation and VDR activity.
4; AML4–5, n = 4) were treated for 72 h with 5-aza (2.5 mM), INEC (10 nM), or
as fold increase expression compared with vehicle (n = 4).
0 nM) for 16 h. Expression of granulocyte differentiation genes (PRTN3 andNE)
ng qPCR.
arrest and impair tumor growth.
h for 16 h. Cell cycle analyses were performed using Topro-3 labeling.
ing qPCR. Results are presented as mean ± SEM.
ts.
t and impair tumor growth. Kaplan-Meier plot of survival of mice treated with
kly), and/or INEC after subcutaneous xenograft with U937 cells (n = 8 tumors in
g via intraperitoneal injection 5 times weekly), and/or INEC (20 mg permouse via
1c mouse bone marrow blasts cell (n = 6).
< 0.01, and ***p < 0.001.
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arrest of clonogenic progenitors and their increased differentia-
tion in vitro, resulting in reduced leukemogenesis and increased
survival in vivo.
DISCUSSION
AML leukemogenesis has been described as a multistep pro-
cess with driver and passenger mutations. Those mutations
can result in a differentiation arrest, deregulation of cell signaling,
and uncontrolled cell proliferation (Welch et al., 2012). VD
signaling induces differentiation and cell growth arrest. There-
fore, targeting VDR might be an interesting therapeutic alterna-
tive in AML. However, life-threatening side effects of VD limit
its use in AML patients.
Here we show that high expression of Vdr and VDR-targeted
gene (CAMP) is associated with an increase of overall patient
survival. In a study of 5,848 AML patients, AML0 subtype was
associated with decreased RFS and OS, suggesting that an
immature phenotype could result in a worsened disease
outcome (Walter et al., 2013). Our studies in AML patients sug-
gest that low Vdr expression could contribute to this poorer
prognosis by preventing AML cell differentiation and/or, more
likely, by preventing LSC exhaustion. In line with the latter hy-
pothesis, among more differentiated AML4/5 subtypes, low
Vdr expression was also associated with a poorer prognosis.
We conclude that VDR is a new genetic modifier significantly
contributing to the expression of different AML subtypes with a
potential impact on disease prognosis and outcome.
Previous studies did not reveal differences in peripheral blood
monocyte numbers in WT and Vdr/ mice, suggesting that Vdr
expression is not essential for monocyte differentiation (O’Kelly
et al., 2002). Our results confirmed that in steady-state condi-
tions monocyte numbers are not altered in Vdr/ mice. In
contrast to mature cells, Vdr inactivation appeared to be essen-
tial for the control of HSC and myeloid progenitor differentiation.
Indeed, HSCs from Vdr/ mice showed an increased quies-
cence status and a reduced ability to accumulate ROS, two char-
acteristics that have been implicated in the protection of HSCs
pool from premature exhaustion, thereby allowing its long-term
maintenance (Amrani et al., 2011; Takubo et al., 2013; Tothova
et al., 2007).Figure 6. VDR Analogs Reduce Stemness of AML Cells
(A) Inecalcitol decreases clonogenicity of Flt3-ITD-transformed cells. Flt3-ITD-tra
in semisolid methylcellulose media containing cytokines (M-3434). When the
replated with or without INEC (10 nM). Third and a fourth rounds of plating were
following 7–10 days of culture. Results are presented as mean ± SEM of four ind
(B and C) Pre-treatment of Flt3-ITD/Npm1c cells resulted in a decrease of LSC c
(B) Flt3-ITD/Npm1c cells were treated with VDR agonist (INEC, 10 nM) or vehicl
entiation.
(C) Flt3-ITD/Npm1c cells treated or not with INEC for 6 days were injected into
Giemsa; top panels) and of grafted cells collected from bone marrow of recipien
(D) Blood parameters, bone marrow, and spleen counts of CD11b+LY6G+ cells o
and non-transplanted naive mice as control (3 months after transplantation).
(E) Spleen appearance and weight of mice receiving, or not (control), Flt3-ITD/Np
(F) Percentage survival of mice injected with Flt3-ITD/Npm1c cells treated or not
(G) Mice were intravenously (i.v.) injected with Flt3-ITD/Npm1c cells treated or no
of mice was determined.
Results are presented as mean ± SEM; nR 3. ns, not significant; *p < 0.05, **pDespite the use of intensive chemotherapy and allogeneic BMT,
relapsed AML remains a disease associated with a poor prog-
nosis. Relapses are associatedwith the presenceof LSCs charac-
terized by their longevity and resistance to chemotherapy. In APL,
it has been shown that targeting RAR results in LSC exhaustion
(Ablain et al., 2013). Here we demonstrate that ablation of Vdr
leads to an increased number of functional HSCs. In a Flt3-ITD/
Npm1c murine model of AML, the use of VDR agonists reduced
engraftment of AML in serial transplantation assay, suggesting
that VDR targeting could impair LSC activity and prevent relapse.
Furthermore, oncogene-transformed Vdr/ cells exhibited
impaired differentiation and increased self-renewal potential, indi-
cating that VDR activation targets major pathways controlling
both cell differentiation and LSC homeostasis. Likewise, VDR ag-
onists promoted AML cell differentiation. Taken together, our data
suggest that activating VDR signaling in AML cells prevents
relapse by decreasing LSC number and therefore VDR agonists
seem a promising therapeutic intervention.
Methylation is a frequent process occurring in mammalian
genome, and genome-wide demethylation is essential for em-
bryo development (Feng et al., 2010). In hematopoiesis epige-
netic modifications also occur, and, for example, 50-CpG-30
dinucleotide demethylation is essential for erythropoiesis
(Shearstone et al., 2011). In hematological malignancies a set
of genes is silenced by epigenetic modifications, resulting in
myeloid differentiation arrest, a feature of AML. However, the
molecular mechanisms resulting in the specificity of gene pro-
moters that are methylated remains poorly understood. Our
data demonstrate that Vdr promoter is methylated in both AML
and CD34+ cells. In agreement, we also show that DNA methyl-
transferase inhibitors (e.g., 5-aza or DAC) can induce Vdr/VDR-
target gene expression. In agreement, in vivo treatment of mice
with a combination of 5-aza and INEC prolonged their survival,
although DAC seemed without effect, probably because of
reduced stability or non-optimal dosage of DAC in the mouse.
These genes may participate not only in cell differentiation block
but also in the prevention of AML progression, mainly by
reducing the pool of LSCs. Therefore, regulation of Vdr expres-
sion by epigenetic modification uncovers a new role for this nu-
clear receptor in AML and explains, at least in part, the effect of
hypomethylating agents in this disease.nsformed bone marrow hematopoietic progenitors (30,000 cells) were plated
number of colonies reached 36 ± 6, the cells were collected, washed, and
done with or without INEC as indicated. Scoring was done for each replating
ependent experiments.
apacity.
e for 6 days. Multiparametric flow cytometry was used to evaluate cell differ-
recipient mice as indicated. Staining of cells before injection (May-Gr€unwald-
t mice (H&E; bottom panels) is shown.
f mice engrafted with Flt3-ITD/Npm1c cells pre-treated with and without INEC
m1c cells treated with or without INEC.
with INEC.
t with INEC, DAC, or both. After secondary transplantation, percentage survival
< 0.01, and ***p < 0.001.
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Our in vitro data demonstrate that there is a potentiation effect
between the VD analog INEC and hypomethylating agents to
induce differentiation, cell growth arrest, and apoptosis of
various AML cell lines and primary AML cells. In agreement,
our in vivo observations using both U937 xenograft model and
Flt3-ITD/Npm1c model show that association of VDR agonists
with hypomethylating agents decreased tumor burden better
than either compound alone. However, in our experimental con-
ditions, this combination did not significantly improve survival on
secondary transplantation over VD analog alone, suggesting that
the latter was sufficient to decrease LSC activity. Therefore, VD
analogs alone might be enough to affect LSCs but not to control
AML blast proliferation. VDR agonists seem a promising thera-
peutic intervention. Targeting CSLs could theoretically lead to
cytopenia because of the exhaustion of HSCs. However, this
phenomenon has not been observed in APL treated with ATRA
and ATO, suggesting that such association remains a clinical op-
tion (Testa and Lo-Coco, 2015). VD administration did not
achieve HSC exhaustion. To our knowledge, there are no consis-
tent data in the literature to support that VD alone is able to
achieve HSC exhaustion in patients despite a large number of
AML patients treated with vitamin D. A refined combination of
VD analogs and hypomethylating agents might be interesting
to control tumor bulk and to prevent relapse. A clinical trial is
ongoing addressing this question (NCT02802267).
In summary, we identified a novel role for Vdr and VDR
signaling in normal and malignant hematopoiesis. The increases
in hematopoietic precursor number andmyeloid progenitor pop-
ulations in Vdr/ mice suggest that Vdr expression is critical for
normal HSC homeostasis. In hematopoietic malignancies, Vdr-
targeted gene expression correlates with improved prognosis
in AML patients, whereas Vdr inactivation in AML cells results
in limited myeloid differentiation and increased clonogenic po-
tential of LSCs. In both AML and CD34+ cells, Vdr expression
might be inactivated by promoter methylation. Conversely,
reversal of Vdr promoter methylation in leukemia cells results
in myeloid differentiation, decrease of LSC number, and reestab-
lishment of responsiveness to VD. Taken together, our data
suggest that Vdr inactivation results in both limited myeloid
differentiation and maintenance of HSC and LSC pools, while in-
duction of VDR signaling decreases LSC numbers, suggesting
that it might be relevant in preventing relapses. This latter effect
may represent a new paradigm potentially applicable to other
malignant diseases.STAR+METHODS
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Anti-CD34 Biolegend Cat# 128607, RRID:AB_1279222
Anti-CD16/32 BD Biosciences Cat# 560541, RRID:AB_1645229
Anti-KI67 Biolegend Cat# 652404, RRID:AB_2561525
Anti-CD127 Biolegend Cat# 121111, RRID:AB_493510
Anti-CD45R Biolegend Cat# 103222, RRID:AB_313005
Anti-LY6G BD Biosciences Cat# 560602, RRID:AB_1727563
Anti-LY6C Biolegend Cat# 128017, RRID:AB_1732093
Anti-CX3CR1 Abcam RRID:AB_306203
Anti-CD11b (human) Biolegend Cat# 301305, RRID:AB_314157
Anti-CD14 (human) Biolegend Cat# 325615, RRID:AB_830688
Anti-rabbit Invitrogen Cat# A-21206, RRID:AB_141708
Biological Samples
Human primary AML Cells Necker University Hospital N/A
Chemicals, Peptides, and Recombinant Proteins
Inecalcitol Hybrigenics N/A
Calcitriol Desma Pharma N/A
Live/dead Thermofischer N/A
Annexin V BD Biosciences N/A
Propidium iodide BD Biosciences N/A
To-Pro-3 Invitrogen N/A
Streptavidin BD Biosciences Cat# 560797, RRID:AB_2033992
5-Azacitidine Celgene N/A
Experimental Models: Cell Lines
HL60 ATCC Cat# CCL-240, RRID:CVCL_0002
OCI-AML3 DSMZ Cat# ACC-582, RRID:CVCL_1844
THP-1 ATCC Cat# TIB-202, RRID:CVCL_0006
U937 ATCC Cat# CRL-1593.2, RRID:CVCL_0007
Experimental Models: Organisms/Strains
Flt3-ITD/ Npm1c, C57BL6 George S. Vassiliou N/A
Female 8-12 weeks old
NMRI-nu Janvier laboratories Cat# TAC:nmrinu, RRID:IMSR_TAC:nmrinu
Female 8-12 weeks old
B6.SJL-PtprcaPepcb/BoyCrl Charles River Cat# CRL:494, RRID:IMSR_CRL:494
Female 8-12 weeks old
57BL/6NCrl Charles River Cat# CRL:475, RRID:IMSR_CRL:475
Female 8-12 weeks old
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
B6.129S4-Vdrtm1Mbd/J Jackson Cat# JAX:006133, RRID:IMSR_JAX:006133
Female 8-12 weeks old
B6.129-Flt3tm1Dgg/J Jackson Cat# JAX:011112, RRID:IMSR_JAX:011112
Female 8-12 weeks old
Oligonucleotides
Primers, see Table S2 this paper N/A
Software and Algorithms
Prism 5 GraphPad Software N/A
FlowJo FlowJo LLC N/ALEAD CONTACT AND MATERIALS AVAILABILITY
This study did not generate new unique reagents. Further information and requests for resources and reagents should be directed to
and will be fulfilled by the Lead Contact, Etienne Paubelle (paubelle-e@chu-caen.fr).
EXPERIMENTAL MODELS AND SUBJECT DETAILS
Clinical samples
All human studies were approved by the institutional review boards of participating institutions. Peripheral bloods cells from AML
patients were obtained after written informed consent. Peripheral blood was collected at the initial diagnosis before the administra-
tion of any treatment. Mononuclear cells were purified by Ficoll-hypaque (PAA laboratories) density centrifugation and resuspended
in DMEM (Invitrogen) supplemented with 15% Fetal Calf Serum (FCS) (Biowest), 100 ng/ml stem cell factor (SCF), 10 ng/ml IL-3 and
25ng/ml FLT3-L (Peprotech).
Cell lines
AML cell lines (Promyeloblastic (HL60), myelocytic (OCI-AML3), monoblastic (THP1 and U937)) were cultured in RPMI-1640 medium
(Invitrogen) supplemented with 10% FCS and antibiotics.
Mice
Vdr/ mice and control Vdr+/+ littermates (Van Cromphaut et al., 2001) were fed ad libitum with a standard rodent diet. All animal
experiments were approved by the ‘‘Institutional Animal Care and Use Committee’’ at Inserm.
Flt3-ITD/ Npm1c mouse model
For Flt3-ITD/ Npm1c model, C57BL6 recipient mice (irradiated with 9 Gy) were injected with 105 bone marrow cells from Flt3-ITD/
Npm1c mice (Mupo et al., 2013) cultured with 10 ng/ml IL-3, 50 ng/ml SCF and 10ng/ml IL-6 (Peprotech) in Stempro medium in
the presence or absence of Inecalcitol (10nM). In some cases injected mice were treated with INEC (20 mg per mouse via intraper-
itoneal injection, five days weekly) or DAC (0.5mg/kg via intraperitoneal injection 5 times weekly). The dose of DACwas adapted from
the dose used for the treatment of patients.
Tumor xenografts
To establish tumors, 10-week old female athymic Nude mice (Janvier laboratories, France) were injected subcutaneously with 5 3
106 U937 mixed with Matrigel (BD Biosciences) (1:1, vol:vol). The mice also received intraperitoneal injections of 5-Azacytidine (Cel-
gene) (5 mg/kg on day 5, 7, 9, 11 and 13), Inecalcitol (Hybrigenics) (20 mg/day 3 times a week), combination of 5-Azacytidine and
Inecalcitol or PBS as a vehicle control. Tumor growth was measured as previously described (Lepelletier et al., 2007).
Human samples microarray analysis
AML and HSPC samples were described previously (Metzeler et al., 2008) and are available at the GEO database. Analysis was per-
formed using R 2.14.0. Raw data were generated using the RMA package. For comparison of different array sets, raw expression
data were normalized to the mean of control GAPDH probe sets.
For methylation analysis, AML and HSPC samples were described previously (Figueroa et al., 2010); (Metzeler et al., 2008) and are
available at the GEO database. The microarray design is documented in accession number GPL6604. Data from this study are pub-
licly available by accessing Gene Expression Omnibus accession number GSE18700. Data were processed using standard pipeline.e2 Cell Reports 30, 739–754.e1–e4, January 21, 2020
METHOD DETAILS
Flow cytometry
Cells were resuspended in flow cytometry buffer (PBS without Mg2+ or Ca2+, 0.5% FCS, 0.1% sodium azide (pH 7.4). Viable cell
counts were obtained using trypan blue staining. For flow cytometric analyses the FcR blocking was performed with 2.4G2 and cells
were immunostained with fluorophore-linked antibodies (BD Biosciences, eBioscience, Biolegend). For immunostaining of lineage
(Lin)-positive cells, a cocktail containing biotin-labeled primary antibodies against CD5, B220, CD11b, 7-4, Gr-1 and Ter-119 (BD
Biosciences) were used, followed by staining with streptavidin-linked fluorophore-labeled secondary antibodies.
Intracellular staining to Ki-67 (Biolegend) was performed using Fix and Perm kit (BD Biosciences). Stained cells were analyzed us-
ing an LSR Fortessa and cell sorting was performed using an Aria II cytometer (BD Biosciences).
ROS levels were evaluated by labeling 1 x106 cells for 30 minutes at 37C with 10 mM of CM-H2DCFDA (5-(and-6)-chloromethyl-
29,79-dichlorodihydrofluorescein diacetate, acetyl ester) redox-sensitive probe (Abcam).
Preparation of recombinant retroviruses
Plasmids encoding human MLL-ENL, MLL-AF9 or Flt3-ITD (kind gift from Dr Patrice Dubreuil, Cancerology Research Centre of Mar-
seille (CRCM), France) were cloned in MSCV-IRES vector. Retroviral production was performed by transient transfection of retroviral
packaging cells (Plat-E, Cell Biolabs) using Lipofectamine LTX plus (Invitrogen). Retrovirus released into the culture supernatant was
used to infect mouse hematopoietic cells as described (Somervaille et al., 2009). Briefly, 4-8 week-oldmicewere injected with 50mg/
kg of 5-FU followed by analysis of bonemarrow cells, flushed from the long bones, 5 days later. Bonemarrow cells were incubated for
48 hours in DMEMwith 15% FCS, 10 ng/ml IL-3, 50 ng/ml SCF and 10ng/ml IL-6 (Peprotech) at 37C to promote cell cycle entry and
then spinoculated with retroviral supernatant on retronectin (Takara) according to the manufacturer’s instructions for 48 hours at
37C.
Cell cycle analysis
For Ki-67/PI staining, the cells were first treated with Fix and Perm reagents according to the manufacturer’s instruction (BD Biosci-
ences), incubated with Ki-67 antibody (16A8, Biolegend), washed and resuspended in PBS with 5 mg/ml RNaseA and Propidium Io-
dide. Stained cells were analyzed using a FACS Fortessa cytometer (BD Biosciences).
Cell death assays
For apoptosis assays, cells were stained with Annexin V and Propidium Iodide according to the manufacturer’s instructions (BD Bio-
sciences) and then analyzed using a FACS Fortessa cytometer (BD Biosciences).
For viability assays, cells were incubated in the presence of different compounds or vehicle controls (e.g., DMSO and ethanol) in
96-well plates at 37C. Celltiter Glo reagents (Promega) were added after 48 to 96 hours to determine cell viability by measuring ATP
levels. The luminescence of each sample was determined in a plate-reading Tecan Infinite M1000 Pro (Tecan) as per manufacturer’s
instructions.
RT and Real-Time PCR analysis
Total RNA was extracted, purified using RNeasy kit (QIAGEN) and subjected to RT (iScript Reverse Transcriptase supermix, Bio-
Rad). Quantitative real-time PCR was performed using a CFX96 PCR system (Bio-Rad), and PCR products were quantified using
Ssofast Eva Green (Bio-Rad). The results of the real-time quantitative PCR were analyzed according to the MIQE guidelines (Bustin,
2010) using the delta-delta Cq method (Livak and Schmittgen, 2001). The complete list of primer sequences is available in Table S2.
Ionizing Radiation
Mice were exposed to sublethal (4.5Gy) or lethal (9.5Gy) total body irradiation using an X-Ray irradiator (Rad Source RS 2000).
Methylcellulose colony-forming assays
Colony formation by oncogene-transformed or healthy mouse cells was examined using Methocult medium (MethoCult GF M3434,
StemCell Technologies). Colonies were scored one week after plating. In serial plating experiments, cells were collected frommeth-
ylcellulose, washed in PBS, counted and replated in freshMethocult media. In some experiments, 10 nM Inecalcitol (hybrigenics) was
added to the culture medium.
Competitive repopulation assays
Lethally irradiated mice were anesthetized before receiving by intravenous injection a mixture of CD45.2 BM cells from Vdrwild-type
or Vdr/ mice (5,000 or 50,000 or 500,000) and 500,000 CD45.1 wild-type competitor cells.Cell Reports 30, 739–754.e1–e4, January 21, 2020 e3
QUANTIFICATION AND STATISTICAL ANALYSIS
The data are expressed as the mean ± SEM. Statistical analyses were performed using Prism 5 software (GraphPad Software, Inc.).
The Student’s t test or the Mann-Whitney test was used to compare two groups, and multigroup comparisons were made using a
one-way ANOVA followed by a post hoc Bonferroni test. We used the Kruskal-Wallis test followed by a post hoc Dunn test for
nonparametric comparisons, where indicated. To compare tumor-free animal curves, the Log-rank test was used. The results
were considered statistically significant at a p value < 0.05 (*), < 0.01 (**), or < 0.001 (***).
DATA AND CODE AVAILABILITY
This study did not generate any unique datasets or code.e4 Cell Reports 30, 739–754.e1–e4, January 21, 2020
